Therapeutic agent and therapeutic device for alleviating ischemia-reperfusion injury

Abstract

Disclosed is a therapy for alleviating ischemia-reperfusion injury, which has few adverse side effects and can inhibit the invasion of neutrophils and the activation of platelets during ischemia reperfusion. The therapy comprises administering a mixed gas through inhalation to a patient who is intended to receive reperfusion, for a period between a time point that is immediately prior to the initiation of the ischemia-reperfusion and a time point that is shortly after the initiation of the reperfusion, wherein the mixed gas comprises 21 to 98% of oxygen, 0.1 to 4% of hydrogen and 40 to 80 ppm of nitrogen monoxide, with the remainder being an inert gas such as a nitrogen gas and a helium gas.

Description

technical field [0001] The present invention relates to a therapeutic agent, a therapeutic device, and a therapeutic method for alleviating damage to affected areas such as myocardium and small blood vessels (ischemia-reperfusion injury) associated with reperfusion seen in reperfusion therapy of acute myocardial infarction, for example. Background technique [0002] In infarction diseases such as myocardial infarction, cerebral infarction, and mesenteric thrombosis, ischemia-reperfusion therapy may be performed in which the infarcted part is mechanically expanded or the thrombus is dissolved, so that the blood flow is cut off. Restoration of blood flow to ischemic tissues. In addition, in the transplanted organ after organ transplantation, the blood flow is similarly restored to the tissue cut off from the blood flow. It is known that when the blood flow is restored, the rapid supply of oxygen to the tissue in the ischemic state will cause various reactions represented by t...

AI Technical Summary

Problems solved by technology

However, it is difficult to suppress the infiltration of neutrophils and the activation of platelets, etc., which are observed during ischemia-reperfusion, only by inhaling hydrogen.

Images